I now have everything needed for a complete, step-by-step management plan. Here it is:
Management of Brucellosis - Step-by-Step
STEP 1: CLINICAL ASSESSMENT & RISK STRATIFICATION
History (critical for diagnosis)
- Occupational exposure: farmer, veterinarian, abattoir worker, lab personnel?
- Dietary: unpasteurized milk, soft goat/sheep cheese, undercooked meat?
- Travel to endemic area (Middle East, Mediterranean, South Asia, Africa)?
- Duration of symptoms (determines acute vs subacute vs chronic classification)
Assess for complications - these change management:
| Complication | Clinical Clues |
|---|
| Spondylitis / sacroiliitis | Severe back/waist pain - present in this patient |
| Neurobrucellosis | Tinnitus, periorbital pain, cranial nerve signs - present in this patient |
| Orchitis/epididymitis | Testicular pain (up to 10% of men) |
| Endocarditis | New murmur, embolic signs |
| Hepatosplenomegaly | Abdominal pain, fullness |
This patient has features suggestive of both spondylitis (back/waist pain) and possible neurobrucellosis (tinnitus + periorbital pain) - this classifies him as COMPLICATED brucellosis, requiring longer therapy.
STEP 2: INVESTIGATIONS
Confirm Diagnosis
| Test | Details |
|---|
| Serum Agglutination Test (SAT / Wright's test) | Titre ≥ 1:160 in endemic areas is presumptive; 4-fold rise over 2 weeks is significant |
| Rose Bengal test | Rapid screening - sensitive but less specific |
| Blood culture x 3 | Alert lab to Brucella risk (biohazard). Sensitivity 10-85%; Bactec systems positive within 7 days |
| Bone marrow culture | More sensitive than blood culture, especially for B. melitensis |
| PCR (NAAT) | Most rapid and sensitive; cannot confirm cure (DNA persists) |
| IgG/IgM ELISA | Useful in chronic/relapsing disease where SAT may be negative |
| Brucella Coombs test | For chronic cases with negative SAT (detects non-agglutinating antibodies) |
Assess Organ Involvement
| Investigation | Purpose |
|---|
| CBC | Anemia, leukopenia, lymphocytosis, thrombocytopenia |
| LFTs | Hepatic involvement (~25% of cases) |
| ESR, CRP | Usually raised in complicated disease |
| MRI lumbar spine | Early spondylodiscitis: anterior end-plate erosions; paravertebral/psoas abscess |
| MRI brain + CSF | If neurobrucellosis suspected - lymphocytosis + low glucose in CSF |
| Echocardiography | If endocarditis suspected |
| Isotope bone scan | More sensitive than plain X-ray; positive even after treatment |
STEP 3: ANTIMICROBIAL THERAPY
This patient is COMPLICATED (probable spondylitis + neurobrucellosis features) - needs triple therapy and extended duration.
A. Uncomplicated Acute Brucellosis (for reference)
Gold standard (WHO preferred):
- Doxycycline 100 mg PO BD x 6 weeks + Streptomycin 1 g IM OD x 2-3 weeks
Alternative (more convenient, slightly higher relapse rate ~10-20%):
- Doxycycline 100 mg PO BD x 6 weeks + Rifampicin 600-900 mg PO OD x 6 weeks
If streptomycin unavailable:
- Doxycycline 200 mg/day x 6 weeks + Gentamicin 3-5 mg/kg/day IM x 1-2 weeks
B. Complicated Brucellosis - Spondylitis / Sacroiliitis (this patient)
- Duration extended to 3 months minimum
- Triple regimen: Doxycycline + Rifampicin + initial Aminoglycoside (Gentamicin x 2 weeks)
- Monitor MRI spine for response
C. Neurobrucellosis (if confirmed by CSF/MRI)
- Duration 3-6 months
- Doxycycline 200 mg/day + Rifampicin 600-900 mg/day + TMP-SMX (co-trimoxazole) for 6+ weeks
- Can add Ceftriaxone 2 g IV q12h x 6 weeks (substitutes for one oral agent - better CNS penetration)
- Steroids may be considered in severe neurobrucellosis with inflammation
"Focal neurologic disease due to Brucella requires prolonged treatment for 3-6 months, usually with ceftriaxone supplementation of a standard two-drug regimen." - Harrison's 22E
STEP 4: SUPPORTIVE MANAGEMENT
- Analgesics / NSAIDs for musculoskeletal pain (back, sacroiliac joints)
- Bed rest in the acute phase; gradual mobilization
- Spinal immobilization/bracing if significant spondylodiscitis on MRI
- Physiotherapy for back pain rehabilitation after acute phase settles
- Neurology referral if confirmed neurobrucellosis
- Orthopedics referral if spinal abscess (paravertebral/psoas) requiring surgical drainage
STEP 5: MONITORING & FOLLOW-UP
| Parameter | Schedule |
|---|
| Clinical reassessment | Weekly for first month |
| SAT serology | At 3 months and 6 months; falling titres confirm response |
| CBC, LFTs | Monthly (drug toxicity monitoring - rifampicin hepatotoxicity, doxycycline GI effects) |
| MRI spine repeat | At 6-8 weeks if spondylitis; document healing |
| Watch for relapse | Occurs in 5-10% with gold-standard regimen; up to 20% with doxycycline + rifampicin |
Signs of relapse (usually 2-3 months after completing therapy):
- Return of fever, sweats, malaise
- Rising SAT titres
- Positive blood culture
- Treat relapse with the same or alternative two-drug regimen for a full 6 weeks
STEP 6: PREVENT COMPLICATIONS & SPECIAL SITUATIONS
| Situation | Action |
|---|
| Brucella endocarditis | Bactericidal drugs (fluoroquinolone + aminoglycoside + beta-lactam); early cardiac surgery (valve replacement) - 84% of brucellosis deaths involve endocarditis |
| Abscess (psoas, paravertebral, splenic) | Surgical drainage + antibiotics ≥6 weeks |
| Prosthetic joint infection | ~75% need debridement or revision + antibiotics |
STEP 7: INFECTION CONTROL & PREVENTION
- Notify public health authorities (notifiable disease in many countries)
- Identify source of infection (animal contact, food source)
- Screen family members and occupational contacts
- Avoid unpasteurized dairy products going forward
- Protective equipment if occupational exposure continues
Summary Drug Chart for This Patient
| Drug | Dose | Route | Duration | Role |
|---|
| Doxycycline | 100 mg BD | Oral | 3 months | Backbone |
| Rifampicin | 600 mg OD | Oral | 3 months | Second agent |
| Gentamicin | 5 mg/kg/day | IM | 2 weeks (initial) | Third agent / aminoglycoside coverage |
| Ceftriaxone | 2 g q12h | IV | 4-6 weeks | Add if neurobrucellosis confirmed |
| Co-trimoxazole | 960 mg BD | Oral | 3 months | If CNS involvement |
"Complex or focal disease may necessitate ≥3 months of therapy. Adherence is very important - poor adherence underlies almost all cases of apparent treatment failure." - Harrison's 22E
Sources: Harrison's Principles of Internal Medicine 22E (2025), Ch. 174 | Goldman-Cecil Medicine, Ch. 286 | Red Book 2021 (AAP Committee on Infectious Diseases)